2. Academic Validation
  3. A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death

A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death

  • Blood Cancer J. 2024 Apr 9;14(1):58. doi: 10.1038/s41408-024-01019-5.
Arghya Ray 1,  Ting Du 2,  Xueping Wan 2,  Yan Song 2,  Sindhu C Pillai 2,  Md Abu Musa 2,  Teng Fang 2,  Jared Moore 3,  Brian Blank 3,  Xiaohui Du 3,  Xi Chen 3,  Robert Warne 3,  Dena Sutimantanapi 3,  Fang Lui 3,  Tatiana Zavorotinskaya 3,  Christophe Colas 3,  Lori Friedman 3,  Melissa R Junttila 3,  Dharminder Chauhan # 4,  Kenneth C Anderson # 5
Affiliations

Affiliations

  • 1 The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. [email protected].
  • 2 The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • 3 ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA.
  • 4 The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. [email protected].
  • 5 The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. [email protected].
  • # Contributed equally.
PMID: 38594241 DOI: 10.1038/s41408-024-01019-5
Abstract

  1. CD73 is the key ectoenzyme involved in the generation of AMP-derived adenosine, which contributes to immunosuppression in the MM BM milieu.

  2. Blocking CD73 activity with a potent, selective, orally bioavailable CD73 Inhibitor ORIC-533 decreases adenosine generation, overcomes immune suppression, and restores immune cell-mediated MM Cell Lysis.

  3. Based on these preclinical studies, a multi-center clinical trial of ORIC-533 has been initiated in patients with relapsed refractory MM (NCT05227144).

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-160696
    CD73 Inhibitor